IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo

Bone

Volumn 51, Issue 4, 2012, Pages 771-780

  Fujii, Toshiya ^a   Kitaura, Hideki ^a   Kimura, Keisuke ^a   Hakami, Zaki Weli ^a   Takano Yamamoto, Teruko ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

IL 4; In vivo; Osteoclast; TNF

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATASE; TARTRATE RESISTANT ACID PHOSPHATASE FORM 5B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; T LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; INTERLEUKIN-4; MALE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865639564     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.024     Document Type: Article

References (37)

1. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
2. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435.
3. Azuma Y., Kaji K., Katogi R., Takeshita S., Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000, 275:4858-4864.
4. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
5. Fuller K., Murphy C., Kirstein B., Fox S.W., Chambers T.J. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002, 143:1108-1118.
6. Kitaura H., Sands M.S., Aya K., Zhou P., Hirayama T., Uthgenannt B., et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J Immunol 2004, 173:4838-4846.
7. Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005, 115:3418-3427.
8. Tracey K.J., Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994, 45:491-503.
9. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993, 9:317-343.
10. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
11. Abu A.Y., Ross F.P., Edwards J., Teitelbaum S.L. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997, 100:1557-1565.
12. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121-136.
13. Kimble R.B., Srivastava S., Ross F.P., Matayoshi A., Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem 1996, 271:28890-28897.
14. Nurmohamed M.T., Dijkmans B.A. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65:661-694.
15. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Yoshida N., Nakayama K. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 2002, 169:4732-4738.
16. Kitaura H., Tatamiya M., Nagata N., Fujimura Y., Eguchi T., Yoshida N., et al. IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett 2006, 107:22-31.
17. Kohara H., Kitaura H., Fujimura Y., Yoshimatsu M., Morita Y., Eguchi T., et al. IFN-gamma directly inhibits TNF-α-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett 2011, 137:53-61.
18. Yoshimatsu M., Kitaura H., Fujimura Y., Eguchi T., Kohara H., Morita Y., et al. IL-12 inhibits TNF-α [U+F020]induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009, 45:1010-1016.
19. Morita Y., Kitaura H., Yoshimatsu M., Fujimura Y., Kohara H., Eguchi T., et al. IL-18 inhibits TNF-α-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. Calcif Tissue Int 2010, 86:242-248.
20. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
21. Wills K.M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999, 17:255-281.
22. Lubberts E., Joosten L.A., Chabaud M., van Den Bersselaar L., Oppers B., Coenen-De Roo C.J., et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710.
23. Wei S., Wang M.W., Teitelbaum S.L., Ross F.P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6622-6630.
24. Lacey D.L., Erdmann J.M., Teitelbaum S.L., Tan H.L., Ohara J., Shioi A. Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology 1995, 136:2367-2376.
25. Shioi A., Teitelbaum S.L., Ross F.P., Welgus H.G., Suzuki H., Ohara J., et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem 1991, 47:272-277.
26. Kitaura H., Nagata N., Fujimura Y., Hotokezaka H., Tatamiya M., Nakao N., et al. Interleukin-4 directly inhibits tumor necrosis factor-α-mediated osteoclast formation in mouse bone marrow macrophages. Immunol Lett 2003, 88:193-198.
27. Nakano Y., Watanabe K., Morimoto I., Okada Y., Ura K., Sato K., et al. Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 1994, 9:1533-1539.
28. Okada Y., Morimoto I., Ura K., Nakano Y., Tanaka Y., Nishida S., et al. Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone 1998, 22:361-365.
29. Lewis D.B., Liggitt H.D., Effmann E.L., Motley S.T., Teitelbaum S.L., Jepsen K.J., et al. Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci U S A 1993, 90:11618-11622.
30. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115:282-290.
31. Takeshita S., Kaji K., Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000, 15:1477-1488.
32. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488.
33. Finkelman F.D., Shea D.T., Morris S.C., Gildea L., Strait R., Madden K.B., et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 2004, 201:139-155.
34. Wei S., Siegal G.P. p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Adv Anat Pathol 2007, 14:42-45.
35. Badger A.M., Griswold D.E., Kapadia R., Blake S., Swift B.A., Hoffman S.J., et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:175-183.
36. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279:1453-1461.
37. Nishikawa M., Myoui A., Tomita T., Takahi K., Nampei A., Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003, 48:2670-2681.